MCID: ACR007
MIFTS: 66

Acromegaly malady

Categories: Rare diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Acromegaly

About this section
Sources:
11Disease Ontology, 46NIH Rare Diseases, 13DISEASES, 52Orphanet, 12diseasecard, 48Novoseek, 37MeSH, 66UMLS, 25GTR, 43NCIt, 29ICD10 via Orphanet, 38MESH via Orphanet, 67UMLS via Orphanet, 60SNOMED-CT
See all MalaCards sources

Aliases & Descriptions for Acromegaly:

Name: Acromegaly 11 46 13 52 12 48 37 66
Growth Hormone Excess 46 25
Growth Hormone-Secreting Pituitary Adenoma 66
 
Somatotroph Adenoma 46
Pituitary Giant 46

Characteristics:

Orphanet epidemiological data:

52
acromegaly:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology11 DOID:2449
MeSH37 D000172
NCIt43 C84533
Orphanet52 ORPHA963
ICD10 via Orphanet29 E22.0
MESH via Orphanet38 D000172
UMLS via Orphanet67 C0001206

Summaries for Acromegaly

About this section
NIH Rare Diseases:46 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (gh). it is most often diagnosed in middle-aged adults, although symptoms can appear at any age. signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. the condition is usually caused by benign tumors on the pituitary called adenomas. rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. when gh-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly. last updated: 4/29/2011

MalaCards based summary: Acromegaly, also known as growth hormone excess, is related to prolactinoma and postural hypotension, and has symptoms including tall stature, abnormality of the tongue and thick lower lip vermilion. An important gene associated with Acromegaly is GNAS (GNAS Complex Locus), and among its related pathways are Ovarian steroidogenesis and Growth hormone receptor signaling. The drugs bromocriptine and octreotide have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related mouse phenotypes are adipose tissue and neoplasm.

Disease Ontology:11 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia:69 Acromegaly is a condition that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 295)
idRelated DiseaseScoreTop Affiliating Genes
1prolactinoma30.9IGF1, POMC, SST
2postural hypotension29.6GH1, GNAS, IGF1, PRL, SST, SSTR5
3pituitary adenoma, prolactin-secreting29.4AIP, GHRH, GNAS, GPR101, IGF1, PRL
4lateral sclerosis29.3GNRH1, INS, POMC, PRL
5diabetes insipidus29.0GHRH, GNRH1, IGF1, INS, POMC, PRL
6pheochromocytoma29.0MEN1, POMC, SST, VIP
7craniopharyngioma28.4GH1, GHRH, GNRH1, INS, POMC, PRL
8obesity27.6GHRH, GNAS, IGF1, IGF2, IGFBP1, IGFBP3
9x-linked intellectual disability-acromegaly-hyperactivity syndrome11.9
10pituitary adenoma, growth hormone-secreting11.8
11pituitary adenoma, growth hormone-secreting 211.4
12spinal muscular atrophy type 1 with congenital bone fractures10.9IGF1, IGFBP3
13acyl-coa dehydrogenase, short-chain, deficiency of10.8GHR, IGF1
14als2-related disorders10.8AIP, GNAS
15pituitary deficiency due to rathke's pouch cysts10.8GH1, GHR, SST
16ovarian mucinous malignant adenofibroma10.8GH1, PRL, SST
17seizures mental retardation hair dysplasia10.8IGF1, IGFBP3, INS
18fumarate hydratase deficiency10.8GH1, GNAS, PRL
19gigantism10.8
20diarrhea 3, secretory sodium, congenital, syndromic10.7IGF1, IGFBP3, INS
21lung large cell carcinoma10.7SST, SSTR2
22hyperinsulinemic hypoglycemia, familial, 510.7IGF1, IGFBP3, INS
23brachial plexus lesion10.7INS, SST
24genetic lipodystrophy10.7PRL, TRH
25short bowel syndrome10.7IGF1, INS, SST
26petrous apex meningioma10.7INS, SST
27brain angioma10.7POMC, SST
28septicemic plague10.6IGF1, IGFBP3, PRL
29strabismus10.6PRL, SST
30lymphedema10.6IGF1, INS, SST
31echolalia10.6GNAS, PRL, TRH
32spinal muscular atrophy10.6INS, SST, VIP
33ossifying fibroma10.6SST, SSTR2, SSTR5
34growth retardation hydrocephaly lung hypoplasia10.6GH1, GHRH, IGF1, IGFBP3
35autoimmune oophoritis10.6GH1, POMC
36hereditary koilonychia10.6GH1, GHRH
37lethal arteriopathy syndrome due to fibulin-4 deficiency10.5AIP, MEN1
38medich giant platelet syndrome10.5AIP, MEN1
39peripheral epithelioid sarcoma10.5GHRH, SST, VIP
40repetitive motion disorders10.5INS, SST
41hypertrichosis10.5IGF1, INS, SST
42immune system organ benign neoplasm10.5IGF1, POMC, PRL
43postpartum depression10.5INS, POMC, PRL
44renal pelvis adenocarcinoma10.5GHRH, POMC, SST
45loeffler endocarditis10.5POMC, PRL, SST
46nasopharyngeal disease10.5POMC, PRL, SST
47breast large cell neuroendocrine carcinoma10.5IGF1, IGFBP3
48gestational choriocarcinoma10.5IGF1, IGFBP1, INS, SST
49benign prostate phyllodes tumor10.5GNRH1, PRL
50sost-related sclerosing bone dysplasia10.5GH1, GNAS, IGF1, PRL, SST

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to acromegaly

Symptoms for Acromegaly

About this section

Symptoms:

 52 (show all 58)
  • long penis
  • abnormality of reproductive system physiology
  • tall stature
  • macroglossia
  • abnormality of the teeth
  • thick lower lip vermilion
  • long face
  • coarse facial features
  • full cheeks
  • mandibular prognathia
  • broad forehead
  • macrotia
  • wide nose
  • synophrys
  • widely spaced teeth
  • depression
  • anxiety
  • impotence
  • abnormality of the endocrine system
  • diabetes mellitus
  • hypertension
  • anterior hypopituitarism
  • acanthosis nigricans
  • hyperhidrosis
  • acne
  • thickened skin
  • large hands
  • tapered finger
  • abnormality of the fingernails
  • joint swelling
  • hoarse voice
  • hypertrophic cardiomyopathy
  • mitral regurgitation
  • broad foot
  • deep plantar creases
  • frontal bossing
  • migraine
  • generalized hirsutism
  • osteoarthritis
  • arthralgia
  • paresthesia
  • spinal canal stenosis
  • cortical diaphyseal thickening of the upper limbs
  • macrodactyly
  • deep palmar crease
  • generalized hyperpigmentation
  • abnormality of the toenails
  • sleep apnea
  • fatigue
  • broad jaw
  • cerebral palsy
  • dysuria
  • palpebral edema
  • dysmenorrhea
  • hypersomnia
  • galactorrhea
  • kyphosis
  • pituitary prolactin cell adenoma

HPO human phenotypes related to Acromegaly:

(show all 45)
id Description Frequency HPO Source Accession
1 tall stature hallmark (90%) HP:0000098
2 abnormality of the tongue hallmark (90%) HP:0000157
3 thick lower lip vermilion hallmark (90%) HP:0000179
4 coarse facial features hallmark (90%) HP:0000280
5 full cheeks hallmark (90%) HP:0000293
6 mandibular prognathia hallmark (90%) HP:0000303
7 broad forehead hallmark (90%) HP:0000337
8 abnormality of the nose hallmark (90%) HP:0000366
9 anterior hypopituitarism hallmark (90%) HP:0000830
10 hyperhidrosis hallmark (90%) HP:0000975
11 joint swelling hallmark (90%) HP:0001386
12 broad foot hallmark (90%) HP:0001769
13 deep plantar creases hallmark (90%) HP:0001869
14 osteoarthritis hallmark (90%) HP:0002758
15 arthralgia hallmark (90%) HP:0002829
16 deep palmar crease hallmark (90%) HP:0006191
17 macrodactyly of finger hallmark (90%) HP:0100746
18 abnormality of the menstrual cycle typical (50%) HP:0000140
19 abnormality of the teeth typical (50%) HP:0000164
20 synophrys typical (50%) HP:0000664
21 behavioral abnormality typical (50%) HP:0000708
22 diabetes mellitus typical (50%) HP:0000819
23 hypertension typical (50%) HP:0000822
24 abnormality of the fingernails typical (50%) HP:0001231
25 abnormality of the voice typical (50%) HP:0001608
26 frontal bossing typical (50%) HP:0002007
27 migraine typical (50%) HP:0002076
28 apnea typical (50%) HP:0002104
29 kyphosis typical (50%) HP:0002808
30 paresthesia typical (50%) HP:0003401
31 spinal canal stenosis typical (50%) HP:0003416
32 abnormality of the toenails typical (50%) HP:0008388
33 cerebral palsy typical (50%) HP:0100021
34 palpebral edema typical (50%) HP:0100540
35 neoplasm of the endocrine system typical (50%) HP:0100568
36 abnormality of reproductive system physiology occasional (7.5%) HP:0000080
37 acanthosis nigricans occasional (7.5%) HP:0000956
38 acne occasional (7.5%) HP:0001061
39 abnormality of the mitral valve occasional (7.5%) HP:0001633
40 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
41 reduced consciousness/confusion occasional (7.5%) HP:0004372
42 generalized hyperpigmentation occasional (7.5%) HP:0007440
43 abnormal renal physiology occasional (7.5%) HP:0012211
44 erectile abnormalities occasional (7.5%) HP:0100639
45 galactorrhea occasional (7.5%) HP:0100829

UMLS symptoms related to Acromegaly:


cushingoid facies, mass of upper limb, mass of lower limb, musculoskeletal and connective tissue signs and symptoms nec, chest wall necrosis, trendelenburg's symptom, extremity contracture, musculoskeletal stiffness, pseudothrombophlebitis

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1insulinPhase 4, Phase 3, Phase 24401
2
OctreotidePhase 4, Phase 3, Phase 2, Phase 120683150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
3
lactitolPhase 4, Phase 3, Phase 1325585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
4
lanreotidePhase 4, Phase 3, Phase 2, Phase 179108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
5
SomatostatinPhase 4, Phase 3, Phase 2, Phase 121238916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
6
CabergolinePhase 4, Phase 34681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
7
DopaminePhase 4, Phase 3, Phase 2367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
8Dopamine agonistsPhase 4, Phase 3611
9
ZincPhase 421547440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
10
protease inhibitorsPhase 45157
Synonyms:
 
protease inhibitors
11
MetforminPhase 41701657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
12
LiraglutidePhase 4293204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
13
MannitolPhase 325769-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
14
histaminePhase 2100975614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
15
Histamine PhosphatePhase 2100851-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
16
DimenhydrinatePhase 243523-87-5441281
Synonyms:
(O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide
2-benzhydryloxyethyl(dimethyl)azanium
8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
8-chloro-1,3-dimethyl-2-oxopurin-6-olate
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
AC1L9AVV
Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
CAS-523-87-5
CHEBI:4604
CID441281
D00520
DB00985
 
Dimenhidrinato
Dimenhydrinate (JP15/USP/INN)
Dimenhydrinatum
Diphenhydramine 8-chlorotheophyllinate
Diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Diphenhydrinate
Dramamine (TN)
HMS1568F12
N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
NCGC00017026-01
O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Prestwick_892
beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
17
Citric AcidPhase 2106377-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
18
EnclomiphenePhase 216115690-57-0
Synonyms:
 
Clomiphene trans-form
19CLOMIPHENEPhase 2161
20
TadalafilPhase 2145171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
21CitrateNutraceuticalPhase 21063
22
Benzocaine17941994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
23
Amiloride502016-88-8, 2609-46-316231
Synonyms:
17440-83-4 (hydrochloride)
1f5l
2016-88-8 (anhydrous hydrochloride)
2609-46-3
3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide
3,5-Diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide
3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
AB00053415
AC-13631
AC1L27IZ
AC1Q3POC
AMILORIDE
AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8))
Amiclaran
Amiclaran (TN)
Amikal (Hydrochloride dihydrate)
Amilorid
Amilorida
Amilorida [INN-Spanish]
Amiloride (INN)
Amiloride HCL
Amiloride [INN:BAN]
Amiloride hydrochloride hydrate
Amiloridum
Amiloridum [INN-Latin]
Amipramidin
Amipramidine
Amipramizid
Amipramizide
Amiprazidine
Amyloride
BCBcMAP01_000101
BIDD:GT0466
BPBio1_000015
BRD-K97181089-003-02-3
BRD-K97181089-310-03-0
BSPBio_000013
BSPBio_001572
BSPBio_001826
Bio1_000359
Bio1_000848
Bio1_001337
Bio2_000292
Bio2_000772
C06821
C6H8ClN7O
CCRIS 6545
CHEBI:2639
CHEMBL945
CID16231
CPD-10324
D07447
DB00594
DivK1c_000182
EINECS 220-024-7
Guanamprazin
 
Guanamprazine
HMS1791O14
HMS1989O14
HMS2089H05
IDI1_000182
IDI1_034042
KBio1_000182
KBio2_000292
KBio2_000394
KBio2_002860
KBio2_002962
KBio2_005428
KBio2_005530
KBio3_000583
KBio3_000584
KBio3_001326
KBioGR_000292
KBioGR_000544
KBioSS_000292
KBioSS_000394
LS-1094
Lopac-A-7410
Lopac0_000111
MK-870 (Hydrochloride dihydrate)
MLS000758249
MLS001060798
Midamor
Midamor (Hydrochloride dihydrate)
MolPort-005-934-472
MolPort-005-937-651
N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide
N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid
N-amidino-3,5-diamino-6-chloropyrazinecarboxamide
NCGC00015089-01
NCGC00015089-02
NCGC00015089-12
NCGC00024443-02
NCGC00024443-05
NCGC00024443-06
NCGC00024443-07
NCGC00024443-09
NINDS_000182
Prestwick0_000007
Prestwick1_000007
Prestwick2_000007
Prestwick3_000007
Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride
SMR000449325
SMR000486264
SPBio_000136
SPBio_001934
ST079279
Spectrum2_000118
Spectrum3_000293
Spectrum4_000132
Spectrum5_000776
Spectrum_000034
Tocris-0890
UNII-7DZO8EB0Z3
ZINC04340269
24
Furosemide18354-31-93440
Synonyms:
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
AKOS000266625
ARONIS24304
Acetic acid potassium salt
Aisemide
Aldalix
Aldic
Aluzine
Anfuramaide
Apo-Frusemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
BIDD:GT0139
BPBio1_000443
BRD-K78010432-001-05-8
BRN 0840915
BSPBio_000401
BSPBio_002054
Beronald
Bio-0044
Bioretic
Bristab
Bristurin
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
CHEBI:47426
CHEMBL35
CID3440
CPD000058202
Cetasix
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic Salt
Diuretic salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
EINECS 200-203-6
Edemid
Edenol
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
FUN
FUROSEMIDE USP
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
Furo-Basan
Furo-Puren
Furo-puren
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide M.D.
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide Monohydrochloride
Furosemide Monosodium Salt
Furosemide [USAN:INN:JAN]
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
 
Golan
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
HSDB 3086
Hissuflux
Hoe-058A
Hydol
Hydrenox
Hydrex
Hydro
Hydro-Rapid
Hydro-rapid
Hydroled
I04-0179
IDI1_000575
Impugan
Jenafusid
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Katlex
Kofuzon
Kolkin
Kutrix
LB 502
LB-502
LS-204
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (TN)
Lasix (tn)
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
Leodrine
Less Diur
Liside
Logirene
Lowpston
Lowpstron
Luscek
MLS001066374
MLS001306403
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
Moilarorin
MolPort-001-641-065
Myrosemide
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
NINDS_000575
NSC 269420
NSC269420
Nadis
Nelsix
Neo-Renal
Neo-renal
Nephron
Nicorol
Novosemide
Octan Draselny
Octan draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall A
Prefemin
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Prestwick_752
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
SAM002264614
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
SPECTRUM1500310
STK177334
Sal Diureticum
Sal diureticum
Salinex
Salix
Salix (brand of furosemide)
Salurex
Salurid
Saluron
Seguril
Selectofur
Sigasalur
Sisuril
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spectrum_001100
Spirofur
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
fulvamide
furosemide
furosemide ''mita''
less Diur
25diuretics1338
26
Ursodeoxycholic acid83128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
27tannic acidNutraceutical1794

Interventional clinical trials:

(show top 50)    (show all 140)
idNameStatusNCT IDPhase
1Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
2Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
3Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
4Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
5Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
6Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
7A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
8A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520Phase 4
9Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
10Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793Phase 4
11Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
12Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Phase 4
13A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.CompletedNCT01861717Phase 4
14Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
15Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
16Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4
17Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4
18Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
19Surgical Debulking of Pituitary AdenomasCompletedNCT01371643Phase 4
20Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227Phase 4
21Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantRecruitingNCT00552851Phase 4
22Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
23Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyRecruitingNCT02115906Phase 4
24Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)RecruitingNCT00915954Phase 4
25Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesRecruitingNCT02427295Phase 4
26Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
27Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetActive, not recruitingNCT01618513Phase 4
28Pasireotide LAR and Pegvisomant Study in AcromegalyActive, not recruitingNCT02668172Phase 4
29Effects of Sandostatin LAR® in AcromegalyActive, not recruitingNCT01424241Phase 4
30Octreotide Efficacy and Safety in First-line Acromegalic PatientsSuspendedNCT00171886Phase 4
31Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
32Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
33Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
34Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3
35Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3
36Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3
37Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
38Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
39Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
40Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
41A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
42Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3
43Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2, Phase 3
44Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
45Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
46Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3
47Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
48Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesRecruitingNCT02354508Phase 3
49Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyRecruitingNCT02685709Phase 3
50Ga-68-DOTATOC -PET in the Management of Pituitary TumoursRecruitingNCT02419664Phase 3

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

About this section

Genetic tests related to Acromegaly:

id Genetic test Affiliating Genes
1 Growth Hormone Excess25

Anatomical Context for Acromegaly

About this section

MalaCards organs/tissues related to Acromegaly:

34
Pituitary, Bone, Testes, Skin, Brain, Pancreas, Lung

FMA organs/tissues related to Acromegaly:

17
Limb

Animal Models for Acromegaly or affiliated genes

About this section

MGI Mouse Phenotypes related to Acromegaly:

39 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053759.4GHR, GNAS, IGF1, IGFBP3, INS, POMC
2MP:00020069.1AIP, GNAS, GNRH1, IGF1, MEN1, POMC
3MP:00053678.6GHR, GNAS, GNRH1, IGF1, IGF2, INS
4MP:00107718.5AIP, GHR, GNAS, GNRH1, IGF1, IGF2
5MP:00053898.3GHR, GHRH, GNRH1, IGF1, IGF2, INS
6MP:00053857.8AIP, GHR, GNAS, IGF1, IGF2, INS
7MP:00053707.7AIP, GHR, GHRH, GNAS, GNRH1, IGF2
8MP:00053867.5GHR, GNAS, IGF2, IGFBP3, INS, POMC
9MP:00036317.3GHR, GHRH, GNAS, GNRH1, IGF1, IGF2
10MP:00053877.3GHR, GHRH, GNAS, GNRH1, IGF1, IGF2
11MP:00053786.9AIP, GHR, GHRH, GNAS, GNRH1, IGF1
12MP:00053796.6AIP, GHR, GHRH, GNAS, GNRH1, IGF1
13MP:00053766.0AIP, GHR, GHRH, GNAS, GNRH1, IGF1

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50)    (show all 1455)
idTitleAuthorsYear
1
Childhood acromegaly due to X-linked acrogigantism: long term follow-up. (27631333)
2016
2
Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. (26530355)
2015
3
Trabecular bone score as a skeletal fragility index in acromegaly patients. (26446771)
2015
4
Acromegaly: assessing the disorder and navigating therapeutic options for treatment. (25374336)
2014
5
A consensus on the diagnosis and treatment of acromegaly complications. (22903574)
2013
6
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. (23291436)
2013
7
Biochemical and quality of life responses to octreotide-LAR in acromegaly. (24178448)
2013
8
Vertebral fracture assessment in acromegaly. (22884713)
2013
9
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. (21744088)
2012
10
Osteoarticular changes in acromegaly. (23008710)
2012
11
Outcome in acromegaly: A retrospective analysis. (23565403)
2012
12
Acromegaly caused by ectopic growth hormone-releasing hormone production from a bronchial carcinoid tumor. (21480145)
2011
13
Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. (21131647)
2011
14
Place of cabergoline in acromegaly: a meta-analysis. (21325455)
2011
15
Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. (20813787)
2010
16
Adrenal lesions in acromegaly: there is a role of metabolic aspects and AIP (Aryl Hydrocarbon Receptor Interacting Protein) gene? Evaluation at baseline and after long term follow-up. (20595802)
2010
17
Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. (20306022)
2010
18
Upper lip bite test in a patient with McCune Albright syndrome with acromegaly. (20036127)
2010
19
Lanreotide for the treatment of acromegaly. (19533047)
2009
20
Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). (18683056)
2009
21
Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. (18418712)
2008
22
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? (18000757)
2008
23
High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. (18284644)
2008
24
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. (17652220)
2007
25
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. (17047390)
2006
26
Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. (16809928)
2006
27
Predictors and rates of treatment-resistant tumor growth in acromegaly. (16061822)
2005
28
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. (16076947)
2005
29
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. (15585549)
2005
30
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. (16159936)
2005
31
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. (16046586)
2005
32
Cardiovascular complications in acromegaly. (15282442)
2004
33
Pegvisomant: a new treatment modality for acromegaly. (16982575)
2004
34
Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. (15743103)
2004
35
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. (14609359)
2003
36
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. (14671148)
2003
37
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. (12364434)
2002
38
Experience with pegvisomant in the treatment of acromegaly. (11527081)
2001
39
Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. (11555849)
2001
40
GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. (11383906)
2001
41
Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. (11083070)
2000
42
Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. (10843197)
2000
43
Growth hormone receptor antagonists therapy for acromegaly. (10909433)
1999
44
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. (8548933)
1995
45
Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values. (8325938)
1993
46
Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly. (7680832)
1993
47
Clinical experience of octreotide in the treatment of acromegaly. (1358345)
1992
48
Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects. (2229278)
1990
49
Somatostatin analog treatment of acromegaly: new aspects. (2900190)
1988
50
Diabetes insipidus and panhypopituitarism after pituitary infarction in a case of acromegaly. (890301)
1977

Variations for Acromegaly

About this section

Clinvar genetic disease variations for Acromegaly:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)single nucleotide variantPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420

Expression for genes affiliated with Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.

Pathways for genes affiliated with Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
19.9GNAS, IGF1, INS
29.9GH1, GHR, PRL
3
Show member pathways
9.9GH1, GHR, PRL
49.8IGF1, IGFBP3, INS
59.6IGF1, IGF2, INS
6
Show member pathways
9.5GH1, IGF1, INS, POMC
79.5GH1, GHR, IGF1, IGF2
89.4GH1, GHR, IGF1, INS, PRL
99.4GHRH, GNAS, POMC, VIP
10
Show member pathways
9.3IGF1, IGF2, IGFBP1, IGFBP3
119.3IGF1, IGF2, IGFBP1, IGFBP3
12
Show member pathways
9.2GH1, GHRH, GNRH1, IGF1, IGF2
13
Show member pathways
9.2GH1, GHRH, GNRH1, IGF1, IGF2
149.0GH1, GHRH, GNAS, GNRH1, IGF1, IGF2
15
Show member pathways
9.0GH1, GHRH, GNAS, GNRH1, IGF1, IGF2
16
Show member pathways
8.7GH1, GHRH, GNAS, GNRH1, IGF1, IGF2
17
Show member pathways
8.3GH1, GHR, GHRH, GNAS, GNRH1, IGF1
18
Show member pathways
7.9GH1, GHR, GHRH, GNAS, GNRH1, POMC
19
Show member pathways
6.3GH1, GHR, GHRH, GNAS, GNRH1, IGF1

GO Terms for genes affiliated with Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor ternary complexGO:004256710.8IGF1, IGFBP3
2insulin-like growth factor binding protein complexGO:001694210.8IGF1, IGFBP3
3secretory granule lumenGO:003477410.4INS, POMC
4extracellular spaceGO:00056157.6GH1, GHR, GHRH, GNRH1, IGF1, IGF2
5extracellular regionGO:00055766.4GH1, GHR, GHRH, GNRH1, IGF1, IGF2

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1growth hormone receptor signaling pathwayGO:006039610.7GH1, GHR
2positive regulation of glycolytic processGO:004582110.7IGF1, INS
3somatostatin signaling pathwayGO:003817010.6SSTR2, SSTR5
4insulin-like growth factor receptor signaling pathwayGO:004800910.6GHR, IGF1
5regulation of insulin-like growth factor receptor signaling pathwayGO:004356710.6IGFBP1, IGFBP3
6JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.5GH1, GHR, PRL
7negative regulation of feeding behaviorGO:200025210.5INS, TRH
8positive regulation of insulin receptor signaling pathwayGO:004662810.5IGF2, INS
9positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.4GH1, GHR, IGF1
10response to nutrientGO:000758410.3IGF1, SST, SSTR2
11positive regulation of JAK-STAT cascadeGO:004642710.3GH1, GHR, PRL
12positive regulation of glycogen biosynthetic processGO:004572510.2IGF1, IGF2, INS
13positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.2GH1, GHRH, IGF1, IGFBP3
14positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.2GH1, IGF1, INS
15insulin receptor signaling pathwayGO:000828610.0IGF2, IGFBP1, INS
16positive regulation of multicellular organism growthGO:00400189.9GH1, GHR, GHRH
17regulation of multicellular organism growthGO:00400149.8GHR, IGF1, PRL
18positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.6GH1, GHR, IGF1, IGF2, INS
19female pregnancyGO:00075659.6GNRH1, IGF1, IGF2, PRL
20positive regulation of MAPK cascadeGO:00434109.6IGF1, IGF2, IGFBP3, INS
21positive regulation of mitotic nuclear divisionGO:00458409.3IGF1, IGF2, INS
22cellular protein metabolic processGO:00442679.2IGF1, IGF2, IGFBP1, IGFBP3, INS, PRL
23positive regulation of cell proliferationGO:00082849.0GHRH, IGF1, IGF2, INS, VIP
24negative regulation of cell proliferationGO:00082858.9GNRH1, IGFBP3, MEN1, SST, SSTR2, SSTR5
25cell-cell signalingGO:00072678.8GHRH, GNRH1, GPR101, INS, POMC, SST

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1prolactin receptor bindingGO:000514810.6GH1, PRL
2somatostatin receptor activityGO:000499410.4SSTR2, SSTR5
3insulin-like growth factor II bindingGO:003199510.4IGFBP1, IGFBP3
4insulin-like growth factor I bindingGO:003199410.4IGFBP1, IGFBP3
5insulin-like growth factor receptor bindingGO:00051599.8GNAS, IGF1, IGF2, INS
6neuropeptide hormone activityGO:00051849.7POMC, TRH, VIP
7insulin receptor bindingGO:00051589.6IGF1, IGF2, INS
8hormone activityGO:00051798.2GH1, GNRH1, IGF1, IGF2, INS, POMC

Sources for Acromegaly

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet